Tiago Fauth
Stock Analyst at Wells Fargo
(3.08)
# 1,169
Out of 5,246 analysts
133
Total ratings
40.74%
Success rate
2.14%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $171 → $217 | $106.24 | +104.25% | 9 | Oct 31, 2025 | |
| WVE Wave Life Sciences | Maintains: Overweight | $21 → $18 | $6.38 | +182.13% | 4 | Sep 4, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $295 → $414 | $568.43 | -27.17% | 7 | Sep 3, 2025 | |
| MNKD MannKind | Maintains: Overweight | $9 → $10 | $3.38 | +195.86% | 2 | Sep 3, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $79 → $73 | $68.81 | +6.09% | 5 | Aug 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $60.98 | -49.16% | 3 | Aug 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $297.45 | +32.80% | 7 | Aug 1, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $23.39 | +177.90% | 8 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $69.12 | +9.95% | 1 | Jun 30, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $5.02 | +39.44% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $29.09 | +247.20% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.21 | +147.93% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $11.19 | +132.35% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $66.82 | +12.24% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $247.05 | -63.97% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $17.24 | +195.82% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $54.09 | +121.85% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $34.15 | -88.29% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $5.10 | +174.51% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $51.08 | +487.37% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $11.25 | +131.11% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $5.20 | +438.46% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $400 | $3.69 | +10,740.11% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.96 | +614.29% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $1.98 | +1,617.17% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $50.15 | -42.17% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $2.65 | +390.57% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $2.76 | +371.01% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $2.61 | -23.37% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $806.46 | -57.84% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $339.30 | -23.67% | 1 | Apr 28, 2021 |
Insmed
Oct 31, 2025
Maintains: Overweight
Price Target: $171 → $217
Current: $106.24
Upside: +104.25%
Wave Life Sciences
Sep 4, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $6.38
Upside: +182.13%
United Therapeutics
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $295 → $414
Current: $568.43
Upside: -27.17%
MannKind
Sep 3, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $3.38
Upside: +195.86%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $79 → $73
Current: $68.81
Upside: +6.09%
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $60.98
Upside: -49.16%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $297.45
Upside: +32.80%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $23.39
Upside: +177.90%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $69.12
Upside: +9.95%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $5.02
Upside: +39.44%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $29.09
Upside: +247.20%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.21
Upside: +147.93%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $11.19
Upside: +132.35%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $66.82
Upside: +12.24%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $247.05
Upside: -63.97%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $17.24
Upside: +195.82%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $54.09
Upside: +121.85%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $34.15
Upside: -88.29%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $5.10
Upside: +174.51%
May 16, 2023
Reiterates: Outperform
Price Target: $300
Current: $51.08
Upside: +487.37%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $11.25
Upside: +131.11%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $5.20
Upside: +438.46%
Mar 24, 2023
Reiterates: Neutral
Price Target: $400
Current: $3.69
Upside: +10,740.11%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.96
Upside: +614.29%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $1.98
Upside: +1,617.17%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $50.15
Upside: -42.17%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $2.65
Upside: +390.57%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $2.76
Upside: +371.01%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $2.61
Upside: -23.37%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $806.46
Upside: -57.84%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $339.30
Upside: -23.67%